Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-374-7580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.52 million
Profitability
Miscellaneous
Employees217
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines Corp (NASDAQ:BPMC) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.83) by $0.15. The biotechnology company earned $0.73 million during the quarter, compared to analyst estimates of $1.38 million. Blueprint Medicines had a negative net margin of 603.88% and a negative return on equity of 59.26%. The business's quarterly revenue was down 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.29) earnings per share. View Blueprint Medicines' Earnings History.
When is Blueprint Medicines' next earnings date?
What price target have analysts set for BPMC?
6 analysts have issued 1-year price targets for Blueprint Medicines' shares. Their forecasts range from $102.00 to $112.00. On average, they anticipate Blueprint Medicines' share price to reach $105.00 in the next year. This suggests a possible upside of 35.3% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.
What is the consensus analysts' recommendation for Blueprint Medicines?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.
Has Blueprint Medicines been receiving favorable news coverage?
Headlines about BPMC stock have been trending somewhat negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Marina Biotech (MRNA), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO) and Perrigo (PRGO).
What other stocks do shareholders of Blueprint Medicines own?
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
- Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
- Mr. Michael Landsittel, Chief Financial Officer (Age 47)
- Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
- Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.20%), BlackRock Inc. (6.96%), Wellington Management Group LLP (5.19%), OppenheimerFunds Inc. (3.50%), Perceptive Advisors LLC (2.60%) and TimesSquare Capital Management LLC (1.75%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Ariel Hurley, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.
Which major investors are selling Blueprint Medicines stock?
BPMC stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Morgan Stanley, Pictet Asset Management Ltd., Opaleye Management Inc., TimesSquare Capital Management LLC, Westfield Capital Management Co. LP, Citigroup Inc. and Wellington Management Group LLP. Company insiders that have sold Blueprint Medicines company stock in the last year include Ariel Hurley, Jeffrey W Albers, Kate Haviland and Marion Dorsch. View Insider Buying and Selling for Blueprint Medicines.
Which major investors are buying Blueprint Medicines stock?
BPMC stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Marshall Wace North America L.P., Laurion Capital Management LP, Cadian Capital Management LP, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc. and Spark Investment Management LLC. View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $77.60.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $3.79 billion and generates $44.52 million in revenue each year. The biotechnology company earns $-236,640,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.
What is Blueprint Medicines' official website?
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
